Vancomycin therapeutic drug monitoring: Is it necessary?

Annals of Pharmacotherapy

Volumn 27, Issue 5, 1993, Pages 594-598

  Freeman, Collin D ^a   Quintiliani, Richard ^b   Nightingale, Charles H ^a  

^a HARTFORD HOSPITAL   (United States)

^b UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VANCOMYCIN;

ANTIBIOTIC THERAPY; ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MONITORING; HUMAN; NEPHROTOXICITY; NONHUMAN; OTOTOXICITY; PATIENT CARE; PRIORITY JOURNAL;

ANIMAL; BACTERIAL INFECTIONS; CHILD, PRESCHOOL; COMPARATIVE STUDY; DRUG MONITORING; EAR DISEASES; HUMAN; INFANT; INFANT, NEWBORN; KIDNEY DISEASES; VANCOMYCIN;

EID: 0027322181     PISSN: 10600280     EISSN: 15426270     Source Type: Journal    
DOI: 10.1177/106002809302700514     Document Type: Article

References (41)

1. Edwards DJ Pancorbo S. Routine monitoring of serum vancomycin concentrations: Waiting for proof of its value. Clin Pharm 1987; 6: 652–4.
2. Rodvold KA Zofuka H Rotschafer JC. Routine monitoring of serum vancomycin concentrations: Can waiting be justified?. Clin Pharm 1987; 6: 655–8.
3. Geraci JE. Vancomycin. Mayo Clin Proc 1977; 52: 631–4.
4. Watanakunakorn C. The antibacterial action of vancomycin. Rev Infect Dis 1981; 3 (Supplementement): S210–S215.
5. Griffith RS. Introduction to vancomycin. Rev Infect Dis 1981; 3 (Supplementement): S200–S204.
6. Louria DB Kaminski T Buchman J. Vancomycin in severe staphylococcal infections. Arch Intern Med 1961; 107: 225–40.
7. Woodley DW Hall WH. The treatment of severe staphylococcal infections with vancomycin. Ann Intern Med 1961; 55: 235–49.
8. Sorrell TC Packham DR Shanker S Foldes M Munro R. Vancomycin therapy for methicillin-resistant Staphylococcus aureus. Ann Intern Med 1982; 97: 344–50.
9. Farber BF Moellering RC. Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981. Antimicrob Agents Chemother 1983; 23: 138–41.
10. Lisby-Sutch SM Nahata MC. Dosage guidelines for the use of vancomycin based on its pharmacokinetics in infants. Eur J Clin Pharmacol 1988; 35: 637–42.
11. Schaad UB McCracken GH Nelson JD. Clinical pharmacology and efficacy of vancomycin in pediatric patients. J Pediatr 1980; 96: 119–26.
12. Peetermans WE Hoogeterp JJ Dokkum Hazekamp-Van AM van den Broek P Mattie H. Antistaphylococcal activities of teicoplanin and vancomycin in vitro and in an experimental infection. Antimicrob Agents Chemother 1990; 34: 1869–74.
13. Ackerman BH Vannier AM Eudy EB. Analysis of vancomycin time-kill studies with Staphylococcus species by using a curve stripping program to describe the relationship between concentration and pharmacodynamic response. Antimicrob Agents Chemother 1992; 36: 1766–9.
14. Healy DP Polk RE Garson ML Rock DT Comstock TJ. Comparison of steady-state pharmacokinetics of two dosage regimens of vancomycin in normal volunteers. Antimicrob Agents Chemother 1987; 31: 393–7.
15. Kirby WMM Perry DM Bauer AW. Treatment of staphylococcal septicemia with vancomycin: Report of thirty-three cases. N Engl J Med 1960; 262: 49–55.
16. Morris AJ Blinsky RT. Prevention of staphylococcal shunt infections by continuous vancomycin prophylaxis. Am J Med Sci 1971; 262: 87–92.
17. Odio C McCracken GH Nelson JD. Nephrotoxicity associated with vancomycin-aminoglycoside therapy in four children. J Pediatr 1984; 105: 491–3.
18. Tange RA Keiviet HL Marie JV Bagger-Sjoback D Ring W. An experimental study of vancomycin-induced cochlear damage. Arch Otorhinolaryngol 1989; 246: 67–70.
19. Lutz H Lenarz T Weidauer H Federspil P Hoth S. Ototoxicity of vancomycin: An experimental study in guinea pigs. ORL J Otorhinolaryngol Relat Spec 1991; 53: 273–8.
20. Brummett RE Fox KE Jacobs F Kempton JB Stokes Z Richmond AB. Augmented gentamicin ototoxicity induced by vancomycin in guinea pigs. Arch Otolaryngol Head Neck Surg 1990; 116: 61–4.
21. Traber PG Levine DP. Vancomycin ototoxicity in a patient with normal renal function. Ann Intern Med 1981; 95: 458–60.
22. Meyerhoff WL Maale GE Yellin W Roland PS. Audiologic threshold monitoring of patients receiving ototoxic drugs. Ann Otol Rhinol Laryngol 1989; 98: 950–4.
23. van der Hulst RJ Boeschoten EW Nielsen FW Struijk DG Dreschler WD Tange RA. Ototoxicity monitoring with ultra-high frequency audiometry in peritoneal dialysis patients treated with vancomycin or gentamicin. ORL J Otorhinolaryngol Relat Spec 1991; 53: Ototoxicity monitoring with ultra-high frequency audiometry in peritoneal dialysis patients treated with vancomycin or gentamicin. 19–22.
24. Waisbren BA Kleinerman L Skemp J Bratcher G. Comparative effectiveness and toxicity of vancomycin, ristocetin, and kanamycin. Arch Intern Med 1960; 106: 179–93.
25. Rybak MJ Albrecht LM Boike SC Chandrasekar PH. Nephrotoxicity of vancomycin, alone and with an aminoglycoside. J Antimicrob Chemother 1990; 25: 679–87.
26. Pauly DJ Musa DM Lestico MR Lindstrom MJ Hetsko CM. Risk of nephrotoxicity with combination vancomycin-aminoglycoside antibiotic therapy. Pharmacotherapy 1990; 10: 378–82.
27. Mellor JA Kingdom J Cafferkey M Keane CT. Vancomycin toxicity: A prospective study. J Antimicrob Chemother 1985; 15: 773–80.
28. Cimino MA Rotstein C Slaughter RL Emrich LJ. Relationship of serum antibiotic concentrations to nephrotoxicity in cancer patients receiving concurrent aminoglycoside and vancomycin therapy. Am J Med 1987; 83: 1091–7.
29. Moellering RC Krogstad DJ Greenblatt DJ. Pharmacokinetics of vancomycin in normal subjects and in patients with reduced renal failure. Rev Infect Dis 1981; 3 (Supplementement): S230–S235.
30. Fitzsimmons WE Postelnick MJ Tortorice PV. Survey of vancomycin monitoring guidelines in Illinois hospitals. Drug Intell Clin Pharm 1988; 22: 598–600.
31. Rybak MJ Boike SC. Monitoring vancomycin therapy. Drug Intell Clin Pharm 1986; 20: 757–61.
32. Matzke GR McGory RW Halstenson CE Keane WF. Pharmacokinetics of vancomycin in patients with various degrees of renal function. Antimicrob Agents Chemother 1984; 25: 433–7.
33. Blouin RA Bauer LA Miller DD Record KE Griffen WO. Vancomycin pharmacokinetics in normal and morbidly obese subjects. Antimicrob Agents Chemother 1982; 21: 575–80.
34. Lake KD Peterson CD. A simplified dosing method for initiating vancomycin therapy. Pharmacotherapy 1985; 5: 340–4.
35. Rotschafer JC Crossley K Zaske D Mead K Sawchuk RJ Solem LD. Pharmacokinetics of vancomycin: Observations in 28 patients and dosage recommendations. Antimicrob Agents Chemother 1982; 22: 391–4.
36. Garrelts JC Godley PJ Horton MW Karboski JA. Accuracy of Bayesian, Sawchuk-Zaske, and nomogram dosing methods for vancomycin. Clin Pharm 1987; 6: 795–9.
37. Gabriel MH Kildoo CW Gennrich JL Modanlou HD Collins SR. Prospective evaluation of a vancomycin dosage guideline for neonates. Clin Pharm 1991; 10: 129–32.
38. Krogstad DJ Moellering RC Greenblatt DJ. Single-dose kinetics of intravenous vancomycin. J Clin Pharmacol 1981; 20: 197–201.
39. Sayers JFB Shimasaki R. Routine monitoring of serum vancomycin concentrations: The answer lies in the middle (letter). Clin Pharm 1988; 7: 18.
40. Garrelts JC Peterie JD. Altered vancomycin dose vs. serum concentration relationship in bum patients. Clin Pharmacol Ther 1988; 44: 9–13.
41. Rybak MJ Albrecht LM Berman JR Warbasse LH Svensson CK. Vancomycin pharmacokinetics in bum patients and intravenous drug abusers. Antimicrob Agents Chemother 1990; 34: 792–5.